Peptide News Network — peptide science, clinical trials, regulation, and industry news

Peptide News Network is a science publication whose stated mission is translating peer-reviewed research into plain language for a general audience. It covers topics across four main sections — Research, Clinical Trials, Regulation, and Industry — and also maintains an Explainers section for foundational science. The site is designed for readers who want to follow developments in peptide science and medicine without needing a specialized background, while still engaging with material that is grounded in the published scientific and regulatory record.

⚠️ Disclaimer: The content on Peptide News Network, and the information in these FAQs, is for general educational purposes only and does not constitute medical advice, diagnosis, or treatment recommendations. Always consult a qualified healthcare professional before making any health-related decisions.

Peptide News Network uses a four-tier Evidence Appraisal system to communicate the strength of the scientific evidence behind each compound it covers. Tiers are assigned based on the quality and depth of research and regulatory standing — not on a compound's popularity or how interesting it is. Tier I contains FDA-approved drugs with large, replicated clinical evidence (5 compounds, including tirzepatide and tesamorelin). Tier II contains compounds with real clinical evidence — often from Phase 1–3 trials — but that are not FDA-approved, or are approved only abroad or for a narrow use (11 compounds, including retatrutide and cagrilintide). Tier III covers compounds that are well characterized in cells and animals but have limited or no human outcome data, and some carry specific safety cautions (22 compounds, including ipamorelin and GHK-Cu). Tier IV covers compounds with early, narrow, or largely single-research-tradition evidence, and in some cases unresolved questions about a compound's identity or sequence (10 compounds, including Melanotan II). The site describes a tier as 'a reading aid, not a verdict.'

⚠️ Disclaimer: This information is general and educational. It is not medical advice. Consult a qualified healthcare professional before using or considering any compound.

According to Peptide News Network, on July 23 and 24, 2026, an FDA advisory committee is scheduled to review seven peptides — including BPC-157, TB-500, and Semax — for placement on the list that determines which substances licensed pharmacists may legally compound. Compounding pharmacy regulations govern whether certain substances can be prepared and dispensed outside of standard FDA drug approval pathways. The outcome of this review could affect the legal status of these peptides within compounding pharmacies in the United States.

⚠️ Disclaimer: This is general regulatory news, not medical advice. Consult a qualified healthcare professional and a licensed pharmacist for guidance relevant to your individual situation.

Peptide News Network explains that GLP-1, GIP, glucagon, and amylin are four gut hormones that form the biological foundation of many headline drugs in metabolic medicine. According to the site's July 2026 explainer, every major drug in this space is built from this short list of hormones, and pharmaceutical companies are increasingly developing drugs that combine activation of more than one of these hormone pathways in a single molecule. For example, Novo Nordisk's investigational drug zenagamtide combines GLP-1 and amylin activation in one molecule and showed effects on blood glucose and weight in a Phase 2 trial in type 2 diabetes. Eli Lilly's retatrutide targets three gut-hormone receptors simultaneously and reported 28% weight loss in a pivotal obesity trial — though the site notes those are topline results not yet peer-reviewed.

⚠️ Disclaimer: Clinical trial results described here reflect published or announced data and do not guarantee outcomes for any individual. This is not medical advice. Speak with your doctor about any treatment options.

Peptide News Network reported that Parabilis Medicines made its Nasdaq debut in June 2026 with an offering priced to raise $670 million, closing at a $770.5 million valuation. The publication described this as a record for the largest venture-backed biotech IPO, and notable specifically because Parabilis is built around a stabilized-peptide platform — a category that has historically been overshadowed by antibody and small-molecule drug companies in terms of investment scale. The site framed this as a signal of growing investor confidence in peptide-based medicine as a distinct drug development category.

⚠️ Disclaimer: This is general industry news for informational purposes only and does not constitute investment advice or medical advice.